{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:15:12Z","timestamp":1790874912581,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Improvement of quality of life (QoL) in patients with sarcoidosis is an important goal of management. The King\u2019s Sarcoidosis Questionnaire (KSQ) and Patient Global Assessment (PGA) are instruments that have been used in sarcoidosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We defined the minimal clinically important difference (MCID) as the within-patient clinically meaningful change threshold and determined the MCID of KSQ general health (KSQ GH), KSQ lung, and PGA using both anchor and distribution methods. The discriminatory properties of these MCIDs relative to other QoL instruments were then determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with sarcoidosis recruited from six centers in the United States were prospectively studied. Initially and at 6 months, patients completed a series of QoL questionnaires, including the St. George\u2019s Respiratory Questionnaire (SGRQ), Short Form 36 (SF-36), Fatigue Assessment Scale (FAS), Sarcoidosis Assessment Tool (SAT), KSQ, and PGA, and spirometry. For the anchor method, receiver operator characteristic curves were used to determine the MCID for improvement or worsening. The distribution method using half of the standard deviation was calculated for KSQ GH, KSQ lung, and PGA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 325 patients enrolled in the study, 271 completed the 6-month evaluation. At 6 months, approximately half of patients were worse and 30% were improved based on previously established MCID values for the SGRQ, SF-36, and FAS. There were no discordant cases. There were significant correlations between the KSQ GH, KSQ lung, and PGA and most parameters assessed. The best correlations were with the SGRQ, SF-36, and FAS, which have established MCID values. Using anchor analysis, we found that most of the domains of SGRQ and SF-36 were able to determine the significant MCIDs for all three variables. These MCIDs were similar to those determined by the half least square method. We propose an MCID of 8 for the KSQ GH, an MCID of 4 for the KSQ lung, and an MCID of 2 for the PGA because these values captured &amp;gt;90% of parameters studied. These MCID values discriminated between changes in other QoL instruments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The determination of MCID values for KSQ lung, KSQ GH, and PGA may prove useful for clinical practice as well as clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202006-607oc","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T16:26:13Z","timestamp":1600964773000},"page":"477-485","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":28,"title":["Evaluating the Minimal Clinically Important Difference of the King\u2019s Sarcoidosis Questionnaire in a Multicenter Prospective Study"],"prefix":"10.1093","volume":"18","author":[{"given":"Robert P.","family":"Baughman","sequence":"first","affiliation":[{"name":"University of Cincinnati Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Judson","sequence":"additional","affiliation":[{"name":"Albany Medical College, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Beaumont","sequence":"additional","affiliation":[{"name":"Clinical Outcomes Solutions, Tucson, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Maier","sequence":"additional","affiliation":[{"name":"National Jewish, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadera J.","family":"Sweiss","sequence":"additional","affiliation":[{"name":"University of Illinois, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Culver","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0723-8209","authenticated-orcid":false,"given":"Edward S.","family":"Chen","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur","family":"Singh","sequence":"additional","affiliation":[{"name":"Foundation for Sarcoidosis Research, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse E.","family":"Lower","sequence":"additional","affiliation":[{"name":"University of Cincinnati Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Reeves","sequence":"additional","affiliation":[{"name":"University of Cincinnati Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7296-8975","authenticated-orcid":false,"given":"Nabeel","family":"Hamzeh","sequence":"additional","affiliation":[{"name":"National Jewish, Denver, Colorado"},{"name":"University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Grutters","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Center of Excellence, Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Valeyre","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale 1272, Universit\u00e9 Sorbonne Paris Nord, Assitance Publique-Hopital de Paris, H\u00f4pital Avicenne, Bobigny, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinder S.","family":"Birring","sequence":"additional","affiliation":[{"name":"Centre for Human and Applied Physiological Sciences, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"2026012203472057500_bib1","doi-asserted-by":"crossref","first-page":"00141","DOI":"10.1183\/23120541.00141-2018","article-title":"Sarcoidosis: patient treatment priorities","volume":"4","author":"Baughman","year":"2018","journal-title":"ERJ Open Res"},{"key":"2026012203472057500_bib2","first-page":"90","article-title":"Endpoints for clinical trials of sarcoidosis","volume":"29","author":"Baughman","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026012203472057500_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/thoraxjnl-2012-201962","article-title":"The development and validation of the King\u2019s Sarcoidosis Questionnaire for the assessment of health status","volume":"68","author":"Patel","year":"2013","journal-title":"Thorax"},{"key":"2026012203472057500_bib4","first-page":"75","article-title":"Validation of the King\u2019s Sarcoidosis Questionnaire (KSQ) in a Dutch sarcoidosis population","volume":"33","author":"Van Manen","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026012203472057500_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12955-019-1131-z","article-title":"Translation and psychometric properties of the King\u2019s Sarcoidosis Questionnaire (KSQ) in German language","volume":"17","author":"Farin","year":"2019","journal-title":"Health Qual Life Outcomes"},{"key":"2026012203472057500_bib6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00408-017-9994-4","article-title":"Repository corticotropin for Chronic Pulmonary Sarcoidosis","volume":"195","author":"Baughman","year":"2017","journal-title":"Lung"},{"key":"2026012203472057500_bib7","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"Judson","year":"2014","journal-title":"Eur Respir J"},{"key":"2026012203472057500_bib8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1164\/rccm.201410-1785OC","article-title":"Validation and important differences for the Sarcoidosis Assessment Tool: a new patient-reported outcome measure","volume":"191","author":"Judson","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203472057500_bib9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1348\/1359107041557048","article-title":"Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS)","volume":"9","author":"De Vries","year":"2004","journal-title":"Br J Health Psychol"},{"key":"2026012203472057500_bib10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1378\/chest.125.3.997","article-title":"Health-related quality of life of persons with sarcoidosis","volume":"125","author":"Cox","year":"2004","journal-title":"Chest"},{"key":"2026012203472057500_bib11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1055\/s-0030-1262216","article-title":"Quality of life in sarcoidosis: assessment and management","volume":"31","author":"De Vries","year":"2010","journal-title":"Semin Respir Crit Care Med"},{"key":"2026012203472057500_bib12","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self-complete measure of health status for chronic airflow limitation: the St. George\u2019s Respiratory Questionnaire","volume":"145","author":"Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"2026012203472057500_bib13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.rmed.2009.09.006","article-title":"The SF-36 and SGRQ: validity and first look at minimum important differences in IPF","volume":"104","author":"Swigris","year":"2010","journal-title":"Respir Med"},{"key":"2026012203472057500_bib14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs","volume":"31","author":"McHorney","year":"1993","journal-title":"Med Care"},{"key":"2026012203472057500_bib15","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.rmed.2011.05.004","article-title":"Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis","volume":"105","author":"de Kleijn","year":"2011","journal-title":"Respir Med"},{"key":"2026012203472057500_bib16","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis: American Thoracic Society\/European Respiratory Society\/World Association of Sarcoidosis and other Granulomatous Disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026012203472057500_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203472057500_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1378\/chest.06-2822","article-title":"Six-minute walk test and health status assessment in sarcoidosis","volume":"132","author":"Baughman","year":"2007","journal-title":"Chest"},{"key":"2026012203472057500_bib19","first-page":"19","article-title":"The WASOG Sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool","volume":"31","author":"Judson","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026012203472057500_bib20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S2213-2600(14)70001-3","article-title":"Minimum clinically important difference for the COPD Assessment Test: a prospective analysis","volume":"2","author":"Kon","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026012203472057500_bib21","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"key":"2026012203472057500_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/MCP.0b013e328273bc2b","article-title":"Six-minute walk test in managing and monitoring sarcoidosis patients","volume":"13","author":"Baughman","year":"2007","journal-title":"Curr Opin Pulm Med"},{"key":"2026012203472057500_bib23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203472057500_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George\u2019s Respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"key":"2026012203472057500_bib25","doi-asserted-by":"crossref","first-page":"e007953","DOI":"10.1136\/bmjopen-2015-007953","article-title":"Minimally important difference estimates and methods: a protocol","volume":"5","author":"Johnston","year":"2015","journal-title":"BMJ Open"},{"key":"2026012203472057500_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12955-018-1055-z","article-title":"Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review","volume":"16","author":"Ousmen","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"2026012203472057500_bib27","article-title":"Methods to identify what is important to patients and select, develop or modify fit-for-purpose clinical outcomes assessments","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"2026012203472057500_bib28","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/thoraxjnl-2013-204119","article-title":"The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference","volume":"69","author":"Kon","year":"2014","journal-title":"Thorax"},{"key":"2026012203472057500_bib29","first-page":"86","article-title":"A composite score to assess treatment response in pulmonary sarcoidosis: the Sarcoidosis Treatment Score (STS)","volume":"36","author":"Baughman","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026012203472057500_bib30","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1440-1843.2012.02134.x","article-title":"Validation of the Sarcoidosis Health Questionnaire in a non-US population","volume":"17","author":"De Boer","year":"2012","journal-title":"Respirology"},{"key":"2026012203472057500_bib31","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1055\/s-0037-1602589","article-title":"Quality of life in sarcoidosis","volume":"38","author":"Judson","year":"2017","journal-title":"Semin Respir Crit Care Med"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/18\/3\/477\/66339041\/annalsats_18_3_477.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/18\/3\/477\/66339041\/annalsats_18_3_477.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:53:05Z","timestamp":1769071985000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/18\/3\/477\/8419587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,1]]},"published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202006-607oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2021,3,1]]},"assertion":[{"value":"2020-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}